High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules.
暂无分享,去创建一个
G. Adams | L. Weiner | R. Schier | J. Marks | R. Alpaugh | R Schier | E. Horak | J D Marks | G P Adams | L M Weiner | A. McCall | H. Simmons | A M McCall | H H Simmons | E M Horak | R K Alpaugh
[1] J. Schlom,et al. Radioimmunolocalization of human carcinoma xenografts with B72.3 second generation monoclonal antibodies. , 1988, Cancer research.
[2] K. Fujimori,et al. Modeling analysis of the global and microscopic distribution of immunoglobulin G, F(ab')2, and Fab in tumors. , 1989, Cancer research.
[3] J. Weinstein,et al. Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. , 1992, Cancer research.
[4] H. Mendonca,et al. Comparisons between two monoclonal antibodies that bind to the same antigen but have differing affinities: uptake kinetics and 125I-antibody therapy efficacy in multicell spheroids. , 1992, Cancer research.
[5] D. Maloney. Preclinical and phase I and II trials of rituximab. , 1999, Seminars in oncology.
[6] P. Trail,et al. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. , 1993, Science.
[7] G. Adams,et al. Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu. , 1998, British Journal of Cancer.
[8] U. K. Laemmli,et al. Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.
[9] I. Bernstein,et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. , 1993, The New England journal of medicine.
[10] R K Jain,et al. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. , 1988, Cancer research.
[11] G. Adams,et al. Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. , 1996, Journal of molecular biology.
[12] J. Mendelsohn,et al. Therapeutic application of anti‐growth factor receptor antibodies , 1998, Current opinion in oncology.
[13] J N Weinstein,et al. A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier. , 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[14] D Tripathy,et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] L L Houston,et al. Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv. , 1993, Cancer research.
[16] S. Batra,et al. Charge-modified single chain antibody constructs of monoclonal antibody CC49: generation, characterization, pharmacokinetics, and biodistribution analysis. , 1999, Nuclear medicine and biology.
[17] R K Jain,et al. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. , 1990, Cancer research.
[18] G. Adams,et al. Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies. , 1998, Cancer research.
[19] J. Huston,et al. In vitro and in vivo characterization of a human anti-c-erbB-2 single-chain Fv isolated from a filamentous phage antibody library. , 1995, Immunotechnology : an international journal of immunological engineering.
[20] E. Vitetta,et al. Redesigning nature's poisons to create anti-tumor reagents. , 1987, Science.